The ERCC1-deficient melanoma cells used were 10-fold more sensitive to cisplatin, leading us to conclude that biochemical inhibition of ERCC1-XPF would need to block > 90% of NER activity and achieve near 10-fold increased sensitivity to cisplatin to be of therapeutic value. This evidence concerns the gene ERCC4 and melanoma.